Healthcare Providers and Services
Company Overview of ViaCord, Inc.
ViaCord, Inc., a cord blood banking company, engages in collecting, processing, testing, and storing cord blood for cord blood and bone marrow transplant patients. It provides cord blood stem cell research services, as well as stem cell preservation service and care to patients, families, and physicians. ViaCord, Inc. also offers customer service, preloaded cord blood collection bag, private courier, and long term storage services for treating juvenile diabetes. The company was founded in 1993 and is based in Cambridge, Massachusetts. ViaCord, Inc. operates as a subsidiary of ViaCell, Inc.
245 First Street
Cambridge, MA 02142
Founded in 1993
Key Executives for ViaCord, Inc.
Chairman of Medical Scientific Advisory Board and Chief Technology Officer
Member of Medical Scientific Advisory Board and Scientific Director of ViaCord Processing Laboratory
Medical Director and Member of Medical Scientific Advisory Board
Compensation as of Fiscal Year 2014.
ViaCord, Inc. Key Developments
ViaCord, Inc. to Advance Cord Blood Stem Cell Therapy Research Through Collaboration with the Center for International Blood and Marrow Transplant Research
Apr 30 13
ViaCord, Inc. is collaborating with the Center for International Blood and Marrow Transplant Research (CIBMTR) to collect, maintain and publish research from ViaCord's cord blood stem cell transplants. This collaboration will expand knowledge of cord blood-derived stem cell applications throughout the medical and research community. To date, CIBMTR's large network of transplant centers has resulted in the development of a clinical database of more than 30,000 cord blood transplant recipients for clinical decision-making, use in studies, and other research purposes with the goal of making a profound impact on the survival of cord blood transplant patients around the world. CIBMTR will work directly with ViaCord to collect and analyze data to better understand the quality and any outcome metrics of ViaCord's released cord blood stem cell units as well as how the units are being used. ViaCord is working with CIBMTR to collect and publish data as well as identify outcomes unique to related or autologous (stem cells from the same patient) transplants. The collaboration will also enable the analysis of umbilical cord units released for potential future use in autologous cell therapy and regenerative medicine clinical trials, including Cerebral Palsy, Type 1 Diabetes and others.
Viacord Releases 250th Cord Blood Stem Cell Unit
Mar 26 13
ViaCord announced the release of its 250(th) umbilical cord blood stem cell unit for use in medical treatments and clinical trials. For nearly 20 years, ViaCord has released life-saving stem cells for disease therapies using a proven method of processing and cryopreserving cord blood. To date, ViaCord has released more units for use in medical treatments and clinical trials than any other family bank. Cord blood stem cells have been used in the treatment of nearly 80 diseases, and more than 30,000 treatments have been conducted worldwide using cord blood stem cells. ViaCord has released stem cells for the treatment of diseases ranging from acute lymphoblastic leukemia, thalassemia major and sickle cell disease. ViaCord's 250th unit was used to treat a patient currently enrolled in the Duke Translational Medicine Institute's Cerebral Palsy Autologous Cord Blood clinical trial conducted at Duke University Medical Center. In this clinical trial, researchers are investigating the potential benefits of autologous reinfusion of cord blood stem cells for children with cerebral palsy.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|